Category: Cordis Corp.
Johnson & Johnson's Cordis Corp. subsidiary touts the 10-year anniversary of the first implantation of its Cypher drug-eluting stent, saying the now-85-year-old patient showed nearly complete coverage a decade after the stent went in.
Cordis Corp. is touting the 10-year anniversary of the first implantation of a drug-eluting stent, saying a now-85-year-old patient showed nearly complete coverage a decade after receiving the first Cypher stent.
The Johnson & Johnson (NYSE:JNJ) subsidiary said a 75-year-old woman was implanted with the sirolimus-eluting device in 1999, to treat a single lesion in the left anterior descending artery. In 2009, angiography, IVUS examination and an optical coherence tomography test showed "a complete coverage of over 90 percent of the analyzed struts," according to a press release.
Appeals Court rules Johnson & Johnson subsidiary did not infringe on patents describing surgical devices coated with therapeutic agents by selling its Cypher drug-eluting stents
Cordis does not use any heat to bond metal to polymer in its Cypher stents and that's more than cool with a federal appeals court.
A three-judge panel for the U.S. Court of Appeals for the Federal Circuit (CAFC) this week affirmed a lower court decision that found Cypher did not infringe on patents held by Effingham, Ill.-based MarcTec LLC -- in effect, siding with the Johnson & Johnson unit because of the way it assembles the drug-eluting stent.
The Superior Court for New Jersey's Appellate Division rules that federal preemption applies to some claims in a product liability lawsuit filed against Johnson & Johnson's Cordis Corp. over coronary stents, but that state laws apply to other claims.
Some product liability claims involving an allegedly defective coronary stent made by Johnson & Johnson's (NYSE:JNJ) Cordis Corp. are preempted by federal law, but state law applies to other claims, according to a ruling by the Superior Court for New Jersey's Appellate Division.
Although the court affirmed the dismissal of some of the claims in lawsuits against Cordis over its Cypher sirolimus-eluting stent, it reversed the dismissal of other claims and remanded the cases back to lower courts.
The results of a trial comparing Abbott's Xience V drug-eluting stent to Boston Scientific's Taxus were published today in the New England Journal of Medicine.
Results from Abbott's (NYSE:ABT) Spirit IV trial, which the company said confirms the superiority of its Xience V drug-eluting stent over Boston Scientific Corp.'s (NYSE:BSX) Taxus, were published today in the New England Journal of Medicine.
The Cleveland Clinic acknowledges that a former employee, Dr. Jay Yadav, did not break the medical center's ethics policy in 2006.
By Mary Vanac
The Cleveland Clinic admitted that a former staff physician and inventor, Dr. Jay Yadav, did not run afoul of the health system’s conflicts of interest policy, as it claimed in 2006 in declining to renew Yadav’s employment contract.
Boston Scientific Corp. appeals a Delaware judge's ruling that a pair of Cordis Corp. stent patents are, after all, enforceable, which overturned her prior decision that the patents were not enforceable.
Boston Scientific Corp. (NYSE:BSX) is looking to run a double-reverse with its appeal of a judge's decision in its long-running war with Johnson & Johnson's (NYSE:JNJ) Cordis Corp. over stent patents.
The Natick, Mass.-based medical device maker filed an appeal with the U.S. Court of Appeals for the Federal Circuit seeking to reverse an August 2009 ruling, which itself reversed a prior decision, regarding the enforceability of a pair of Cordis Corp. patents.
Johnson & Johnson subsidiary Cordis Corp. enrolls the first patients in the Innovation clinical trial of its InCraft stent graft to treat abdominal aortic aneurysms.
Cordis Corp. enrolled the first patients in a clinical trial of a stent graft designed to treat abdominal aortic aneurysms.
The Bridgewater, N.J.-based Johnson & Johnson (NYSE:JNJ) subsidiary said the Innovation study of its InCraft stenting system will assess the device's safety, with up to 25 patients enrolled at three sites in Germany.
